ES2054668T3 - Composicion farmaceutica util para el tratamiento de carcinomas y otras enfermedades y un proceso para la preparacion del componente activo y de la composicion farmaceutica. - Google Patents

Composicion farmaceutica util para el tratamiento de carcinomas y otras enfermedades y un proceso para la preparacion del componente activo y de la composicion farmaceutica.

Info

Publication number
ES2054668T3
ES2054668T3 ES87304427T ES87304427T ES2054668T3 ES 2054668 T3 ES2054668 T3 ES 2054668T3 ES 87304427 T ES87304427 T ES 87304427T ES 87304427 T ES87304427 T ES 87304427T ES 2054668 T3 ES2054668 T3 ES 2054668T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
carcinomas
diseases
treatment
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87304427T
Other languages
English (en)
Inventor
Juan Carlos Vidal
Luis Alberto Costa
Plata Guillermo Jose Hernandez
Molina Carlos Maria Coni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventech Research Inc
Original Assignee
Ventech Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventech Research Inc filed Critical Ventech Research Inc
Application granted granted Critical
Publication of ES2054668T3 publication Critical patent/ES2054668T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPLEJO DE CROTOXINA SUBGRUPOS A Y B OBTENIBLE MEDIANTE SEPARACION CROMATOGRAFICA A PARTIR DE VENENO EN BRUTO DE CROTALUS DURSSUS TERRIFICUS, ES UTIL PARA EL TRATAMIENTO DE CARCINOMAS Y TRASTORNOS VASCULARES, INFECCIOSOS O ENDOCRINOS, TALES COMO DIABETES, Y PARA EL TRATAMIENTO DEL DOLOR EN GENERAL.
ES87304427T 1986-05-19 1987-05-19 Composicion farmaceutica util para el tratamiento de carcinomas y otras enfermedades y un proceso para la preparacion del componente activo y de la composicion farmaceutica. Expired - Lifetime ES2054668T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AR30400686 1986-05-19
AR30419586 1986-06-02

Publications (1)

Publication Number Publication Date
ES2054668T3 true ES2054668T3 (es) 1994-08-16

Family

ID=25590979

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87304427T Expired - Lifetime ES2054668T3 (es) 1986-05-19 1987-05-19 Composicion farmaceutica util para el tratamiento de carcinomas y otras enfermedades y un proceso para la preparacion del componente activo y de la composicion farmaceutica.

Country Status (4)

Country Link
EP (1) EP0246861B1 (es)
JP (1) JPH0720875B2 (es)
DE (1) DE3784768T2 (es)
ES (1) ES2054668T3 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010776A1 (en) * 1996-09-11 1998-03-19 Shanahan Prendergast Elizabeth Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms
SG129211A1 (en) * 1997-11-06 2007-02-26 Univ Singapore Therapeutic molecules
AU767940B2 (en) 1999-07-14 2003-11-27 S.I.S Shulov Institute For Science Ltd. Analgesic from snake venom
RU2261719C2 (ru) * 2000-10-27 2005-10-10 Писарев Александр Геннадьевич Водно-спиртовая настойка
EP1391207A1 (en) * 2001-04-24 2004-02-25 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
DE10322656A1 (de) * 2003-05-20 2004-12-09 Toximed Gmbh Pharmazeutischer Wirkstoff
CN101048170B (zh) * 2004-05-06 2011-04-13 生物合成实验室有限公司 源自响尾蛇crotalus durissus terrificus蛇毒的止痛肽的类似化合物、它们的用途、组合物、 制备和纯化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE675605C (de) * 1936-09-11 1939-06-02 August Wolff Sudbracker Naehrm Verfahren zur Trennung und Gewinnung der wertvollen Bestandteile des Bienen- und Schlangengiftes
US4341762A (en) * 1981-04-07 1982-07-27 Haast William E Use of snake venoms for treatment of neurological and related disorders

Also Published As

Publication number Publication date
JPS6333334A (ja) 1988-02-13
JPH0720875B2 (ja) 1995-03-08
EP0246861A2 (en) 1987-11-25
DE3784768D1 (de) 1993-04-22
EP0246861B1 (en) 1993-03-17
DE3784768T2 (de) 1993-06-24
EP0246861A3 (en) 1989-01-04

Similar Documents

Publication Publication Date Title
MX27046A (es) 5-arilalquil-4-alcoxy-2(5h)-furanonas, productos intermedios y procedimiento para su preparacion asi como su aplicacion como sustancia activa terapeutica.
NO146456C (no) Fremgangsmaate for fremstilling av kapsellegeme, saerlig for medisindoseringskapsel
ES2026708T3 (es) Jeringa de dos camaras con una carga de proteina humana sensible a la actividad como principio activo.
IE38602L (en) Aryloxyalkanolamine derivatives
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
ES2054668T3 (es) Composicion farmaceutica util para el tratamiento de carcinomas y otras enfermedades y un proceso para la preparacion del componente activo y de la composicion farmaceutica.
ES2067250T5 (es) Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.
SE7409387L (es)
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
Fritz et al. Plasma levels and efficacy of imipramine treatment for enuresis
Bruguerolle et al. Temporal variations in transcutaneous passage of drugs: the example of lidocaine in children and in rats
CY1108648T1 (el) Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας
NO873273L (no) Flergranultablett for avgivelse av en aktiv bestanddel over tid.
ES2061495T3 (es) Peptidos relacionados con el virus htlv-iii, anticuerpos para los peptidos, vacunas, inmunizacion activa y pasiva contra el virus del sida y prueba diagnostica para la deteccion serologica del virus del sida.
Burce et al. Immunological interactions between Trichinella spiralis and Trichuris muris in the intestine of the mouse
EP1050309A4 (en) PROMOTER OF THE SECRETION OF NEUROTROPHIC FACTORS
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
Strong et al. Conservative treatment of Morton's neuroma
Belova et al. Possibilities of cavinton therapy regimen for infusions and cavinton comforte in acute and early recovery periods after ischemic stroke
Burch et al. Time course of plasma drug levels during once-daily oral administration of clomipramine
Perlman A study of the therapeutic action and toxicity of pentaerythritol tetranitrate
Breckenridge Oral anticoagulants--the totem and the taboo
Hermans et al. Preliminary results on clinical and immunological effects of thymus hormone preparations in AIDS
Innerfield et al. Plasma antithrombin elevations in buccal varidasetreated patients
SU569310A1 (ru) Вещество,про вл ющее туберкулостатическую активность

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 246861

Country of ref document: ES